Inside the assumptions and interactive model behind our $617b longevity biotech TAM – and why you need not agree with us. With thanks to MuseCell Innovations, sponsor of the Longevity Biotech Report.

$71 million facility in Vilnius will manufacture patient-by-patient treatments, with ambitions stretching into longevity medicine. There was a ribbon, a crowd, the usual photo line-up of executives ...

Twelve candidate aging rate indicators could offer faster route to testing geroprotective drugs – and to understanding what ...

Yale-led analysis harmonized 51 studies under one standardized pipeline, and senolytics came out looking shaky.

New Princeton lab gives skincare-focused biotech direct control over research behind its flagship rapalog serum, rather than ...

PhytoGaia spotlights new clinical data on ingredients for healthy aging, liver support and, notably, pet wellness. Walk the ...

Phase 3 results presented in Munich and Barcelona show gains for two life-threatening conditions that quietly steal years ...

At a Munich cardiology congress, a Korean startup’s ring-shaped monitor drew crowds asking how fast they could buy in bulk. Ask any startup founder what a good trade show looks like, and most will ...

Mission Therapeutics pairs brain-penetrant mitochondria drug with NeuraLight’s eye-tracking biomarkers in a multi-country ...

New MOU pairs GlycanAge’s glycan-based biological age test with ExoEarth’s exosome platform, bringing inflammaging testing ...

The company has launched The Elysium Longevity Institute, a physician-led clinical program meant to bring rigor to a field ...